Top

Journal of Orthopaedic Science

Published in:

01-09-2013 | Original Article

Osteoprotective effect of propranolol in ovariectomized rats: a comparison with zoledronic acid and alfacalcidol

Authors: Deepak Kumar Khajuria, Rema Razdan, D. Roy Mahapatra, M. R. Bhat

Published in: Journal of Orthopaedic Science | Issue 5/2013

Abstract

Background

Currently β-adrenergic receptor blockers are considered to be potential drugs under investigation for preventive or therapeutic effect in osteoporosis. However, there is no published data showing the comparative study of β-blockers with well accepted agents for the treatment of osteoporosis. To address this question, we compared the effects of propranolol with well accepted treatments like zoledronic acid and alfacalcidol in an animal model of postmenopausal osteoporosis.

Methods

Five days after ovariectomy, 36 ovariectomized (OVX) rats were divided into 6 equal groups, randomized to treatments zoledronic acid (100 μg/kg, intravenous single dose); alfacalcidol (0.5 μg/kg, oral gauge daily); propranolol (0.1 mg/kg, subcutaneously 5 days per week) for 12 weeks. Untreated OVX and sham OVX were used as controls. At the end of treatment serum calcium and alkaline phosphatase were assayed. Femurs were removed and tested for bone density, bone porosity, bone mechanical properties and trabecular micro-architecture.

Results

Propranolol showed a significant decrease in alkaline phosphatase levels and bone porosity in comparison to OVX control. Moreover, propranolol significantly improved bone density, bone mechanical properties and inhibited the deterioration of trabecular microarchitecture when compared with OVX control. The osteoprotective effect of propranolol was comparable with zoledronic acid and alfacalcidol.

Conclusions

Based on this comparative study, the results strongly suggest that propranolol can be a candidate therapeutic drug for the management of postmenopausal osteoporosis.

Khajuria DK, Razdan R, Mahapatra DR. Drugs for the management of osteoporosis: a review. Rev Bras Reumatol. 2011;51:365–82.PubMedCrossRef

Hohenhaus MH, McGarry KA, Col NF. Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option? Drugs. 2007;67:2311–21.PubMedCrossRef

Togari A. Adrenergic regulation of bone metabolism: a possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc Res Tech. 2002;58:77–84.PubMedCrossRef

Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434:514–20.PubMedCrossRef

Pogoda P, Egermann M, Schnell JC, Priemel M, Schilling AF, Alini M, Schinke T, Rueger JM, Schneider E, Clarke I, Amling M. Leptin inhibits bone formation not only in rodents, but also in sheep. J Bone Miner Res. 2006;21:1591–9.PubMedCrossRef

Graham S, Hammond-Jones D, Gamie Z, Polyzois I, Tsiridis E. The effect of β-blockers on bone metabolism as potential drugs under investigation for osteoporosis and fracture healing. Expert Opinion Investig Drugs. 2008;17:1281–99.CrossRef

Bonnet N, Laroche N, Vico L, Dolleans E, Benhamou LC, Courteix D. Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J Pharmacol Exp Ther. 2006;318:1118–27.PubMedCrossRef

Bonnet N, Benhamou CL, Malaval L, Goncalves C, Vico L, Eder V, Pichon C, Courteix D. Low dose beta-blocker prevents ovariectomy-induced bone loss in rats without affecting heart functions. J Cell Physiol. 2008;217:819–27.PubMedCrossRef

Sliwiñski L, Folwarczna J, Kaczmarczyk-Sedlak I, Pytlik M, Cegiela U, Trzeciak HI. Effects of propranolol on the skeletal system of non-ovariectomized and ovariectomized rats. Calcif Tissue Int. 2008;82:S224–5.

10.

Baek K, Bloomfield SA. β-Adrenergic blockade and leptin replacement effectively mitigate disuse bone loss. J Bone Miner Res. 2009;24:792–9.PubMedCrossRef

11.

Bonnet N, Gadois C, McCloskey E, Lemineur G, Lespessailles E, Courteix D, Benhamou CL. Protective effect of β-blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone. 2007;40:1209–16.PubMedCrossRef

12.

de Vries F, Souverein PC, Cooper C, Leufkens HG, van Staa TP. Use of β-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int. 2007;80:69–75.PubMedCrossRef

13.

Meisinger C, Heier M, Lang O, Döring A. β-Blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study. Osteoporos Int. 2007;18:1189–95.PubMedCrossRef

14.

Purchase-Helzner EL, Cauley JA, Faulkner KA, Pratt S, Zmuda JM, Talbott EO, Hochberg MC, Ston K, Newman A. Hearing sensitivity and the risk of incident falls and fracture in older women: the study of osteoporotic fractures. Ann Epidemiol. 2004;14:311–8.PubMedCrossRef

15.

Khajuria DK, Razdan R, Mahapatra DR. Description of a new method of ovariectomy in female rats. Rev Bras Reumatol. 2012;52:466–70.CrossRef

16.

Cheng Z, Yao W, Zimmermann EA, Busse C, Ritchie RO, Lane NE. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats. J Bone Miner Res. 2009;24:209–20.PubMed

17.

Iwamoto J, Seki A, Takeda T, Sato Y, Yamada H, Yeh JK. Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats. Exp Animals. 2006;55:357–67.CrossRef

18.

Schneider PE, Miller HI, Nakamoto T. Effects of caffeine intake during gestation and lactation on bones of young growing rats. Res Exp Med. 1990;190:131–6.CrossRef

19.

Crandall SH, Dahl NC, Lardner TJ. An introduction to the mechanics of solids. 2nd ed. New York: McGraw-Hill; 1978.

20.

Sirois I, Cheung AM, Ward WE. Biomechanical bone strength and bone mass in young male and female rats fed a fish oil diet. Prostaglandins Leukot Essent Fatty Acids. 2003;68:415–21.PubMedCrossRef

21.

Ulrich D, van Rietbergen B, Laib A, Ruegsegger P. The ability of three-dimensional structural indices to reflect mechanical aspects of trabecular bone. Bone. 1999;25:55–60.PubMedCrossRef

22.

Hildebrand T, Rüegsegger P. Quantification of bone microarchitecture with the structure model index. Comput Methods Biomech Biomed Eng. 1997;1:15–23.CrossRef

23.

Zhang Y, Lai WP, Leung PC, Wu CF, Wong MS. Short- to mid term effects of ovariectomy on bone turnover, bone mass and bone strength in rats. Biol Pharm Bull. 2007;30:898–903.PubMedCrossRef

24.

Jiang G, Matsumoto H, Yamane J, Kuboyama N, Akimoto Y, Fujii A. Prevention of trabecular bone loss in the mandible of ovariectomized rats. J Oral Sci. 2004;46:75–85.PubMedCrossRef

25.

Sahana H, Khajuria DK, Razdan R, Mahapatra DR, Suresh S, Rao RR, Marippan L. Improvement in bone properties by risedronate adsorbed hydroxyapatite novel nanoparticle formulation in rat model of postmenopausal osteoporosis. J Biomed Nanotechnol. 2012;9:1–9.

26.

Donahue HJ, Mazzeo RS, Horvath SM. Endurance training and bone loss in calcium-deficient and ovariectomized rats. Metabolism. 1988;37:741–4.PubMedCrossRef

27.

Liu JM, Zhao HY, Ning G, Chen Y, Zhang LZ, Sun LH, Zhao YJ, Xu MY, Chen JL. IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and postmenopausal women. J Bone Miner Metab. 2008;26:159–64.PubMedCrossRef

28.

Shiraishi A, Miyabe S, Nakano T, Umakoshi Y, Ito M, Mihara M. The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis. BMC Musculoskelet Disord. 2009;10:66.PubMedCrossRef

29.

Prabhakara RN, Lakshmana M. Prevention of bone loss in calcium deficient ovariectomized rats by OST-6, a herbal preparation. J Ethnopharmacol. 2003;84:259–64.CrossRef

30.

Ott SM. Fractures after long-term alendronate therapy. J Clin Endocrinol Metab. 2001;86:1835–6.PubMedCrossRef

Title: Osteoprotective effect of propranolol in ovariectomized rats: a comparison with zoledronic acid and alfacalcidol
Authors: Deepak Kumar Khajuria
Rema Razdan
D. Roy Mahapatra
M. R. Bhat
Publication date: 01-09-2013
Publisher: Springer Japan
Published in: Journal of Orthopaedic Science / Issue 5/2013
Print ISSN: 0949-2658
Electronic ISSN: 1436-2023
DOI: https://doi.org/10.1007/s00776-013-0433-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Osteoprotective effect of propranolol in ovariectomized rats: a comparison with zoledronic acid and alfacalcidol

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2013

Factors influencing the residual rib hump after posterior spinal fusion for adolescent idiopathic scoliosis with Lenke 1 and 2 curves

Reliability, validity, and responsiveness of the Japanese version of the patient-rated elbow evaluation

Hormonal therapy with external radiation therapy for metastatic spinal cord compression from newly diagnosed prostate cancer

More radial shortening after low-energy Colles’ fractures is associated with type 2 diabetes mellitus among postmenopausal women, irrespective of bone mineral density

The Pavlik harness in the treatment of developmentally dislocated hips: results of Japanese multicenter studies in 1994 and 2008

Overview of medical device regulation in Japan as it relates to orthopedic devices